- Home
- MAC vs APGE Comparison
MAC vs APGE Comparison
Compare MAC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | APGE |
|---|---|---|
| Founded | 1964 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MAC | APGE |
|---|---|---|
| Price | $18.84 | $65.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.34 | ★ $103.33 |
| AVG Volume (30 Days) | ★ 1.9M | 1.0M |
| Earning Date | 02-18-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,099,978,000.00 | N/A |
| Revenue This Year | $10.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.55 | N/A |
| 52 Week Low | $12.48 | $26.20 |
| 52 Week High | $20.99 | $84.56 |
Technical Indicators
Market Signals| Indicator | MAC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 39.67 |
| Support Level | $19.05 | $60.35 |
| Resistance Level | $19.74 | $66.18 |
| Average True Range (ATR) | 0.51 | 4.55 |
| MACD | 0.05 | -0.75 |
| Stochastic Oscillator | 56.77 | 27.71 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.2 million square feet of gross leasable area and averaged $849 sales per square foot over the 12 months ended in June 2025.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.